| Feature |
Biliary Colic |
Acute Cholecystitis |
| Pain Characteristics |
- Location: RUQ or epigastric
- Radiation: To right scapula, right shoulder, or interscapular region
- Onset: Sudden, often postprandial (30-90 min after fatty meal)
- Duration: 30 minutes to 6 hours (typically 2-4 hours)
- Character: Severe, constant, crescendo pattern (despite term "colic")
- Resolution: Gradual resolution once stone dislodges
|
- Location: RUQ (more localized than biliary colic)
- Radiation: To right scapula or shoulder
- Onset: May begin as biliary colic that doesn't resolve
- Duration: Persistent, > 6 hours (often days)
- Character: Severe, constant, progressively worsening
- Resolution: Does not resolve spontaneously
|
| Associated Symptoms |
- Nausea and vomiting (common)
- No fever
- No chills/rigors
- Patient may appear uncomfortable but not toxic
|
- Nausea and vomiting (very common)
- Fever (low-grade 38-38.5°C typical; higher suggests complications)
- Chills (may occur)
- Anorexia
- Patient appears ill, may be toxic if complicated
|
| Physical Examination |
- Vital signs: Normal temperature, may have mild tachycardia
- Abdominal exam:
- RUQ tenderness (mild to moderate)
- No peritoneal signs
- No guarding or rebound
- Murphy's sign: Negative
- Boas's sign: Absent
- Examination between episodes is usually normal
|
- Vital signs: Low-grade fever, tachycardia; hypotension if septic
- Abdominal exam:
- Marked RUQ tenderness
- Voluntary guarding
- May have involuntary guarding if peritonitis
- Rebound tenderness (suggests peritonitis)
- Murphy's sign: POSITIVE (97% sensitive, 48% specific)
- Inspiratory arrest with deep palpation of RUQ during deep inspiration
- Pain causes sudden cessation of inspiration
- Boas's sign: May be present
- Hyperesthesia (increased sensitivity to touch) in the region below the right scapula
- Due to referred visceral pain via phrenic nerve irritation
- Palpable mass: May palpate distended, tender gallbladder (30% of cases)
- Jaundice: Uncommon (< 10%), suggests Mirizzi syndrome or CBD stones
|
| Test |
Biliary Colic |
Acute Cholecystitis |
| White Blood Cell Count |
Normal (4,000-11,000/μL) |
- Elevated: 12,000-15,000/μL (leukocytosis)
- Left shift (bandemia) indicates bacterial infection
- > 20,000 suggests complications (gangrene, perforation)
|
| Bilirubin |
Normal |
- Usually normal or mildly elevated (< 4 mg/dL)
- Significant elevation suggests:
- Concomitant CBD stones
- Mirizzi syndrome (stone in cystic duct compressing CBD)
|
| Alkaline Phosphatase |
Normal |
Mildly elevated (up to 2x upper limit normal) in 25% of cases |
| Transaminases (AST/ALT) |
Normal |
- Normal or mildly elevated (< 300 U/L)
- Marked elevation suggests choledocholithiasis or hepatitis
|
| Amylase/Lipase |
Normal |
- Usually normal
- Elevated if concomitant gallstone pancreatitis
|
| C-Reactive Protein |
Normal or mildly elevated |
Elevated (> 3 mg/dL); higher levels correlate with severity |
| Blood Cultures |
Not indicated |
- Positive in 10-30% with acute cholecystitis
- Obtain if fever/sepsis present
|
| Imaging Modality |
Biliary Colic |
Acute Cholecystitis |
| RUQ Ultrasound (First-line) |
- Gallstones present: Echogenic foci with posterior acoustic shadowing, mobile with position changes
- Gallbladder wall: Normal thickness (< 3 mm)
- Pericholecystic fluid: Absent
- Sonographic Murphy's sign: Negative (no maximal tenderness when probe pressed over gallbladder)
- CBD: Normal caliber (< 6 mm, or < 10 mm if post-cholecystectomy)
|
- Gallstones present: Often see stone impacted in gallbladder neck or cystic duct
- Gallbladder wall thickening: > 3-4 mm (highly suggestive if > 5 mm)
- Wall edema: "Double wall sign" or hypoechoic layer
- Pericholecystic fluid: Present (fluid collection around gallbladder)
- Sonographic Murphy's sign: POSITIVE (most specific finding - 95% PPV)
- Gallbladder distension: Length > 10 cm or width > 5 cm
- Gas in gallbladder wall: Suggests emphysematous cholecystitis (surgical emergency)
- Sensitivity/Specificity: 88-95% sensitive, 78-80% specific
|
| HIDA Scan (Cholescintigraphy) |
- Gallbladder fills normally with radiotracer
- Normal emptying with CCK stimulation
- Tracer visualized in CBD and small bowel
|
- Non-visualization of gallbladder after 4 hours: Diagnostic (indicates cystic duct obstruction)
- Radiotracer seen in liver and CBD, but not gallbladder
- Sensitivity: 95%
- Specificity: 90%
- Best use: When ultrasound equivocal but clinical suspicion high
- Limitations: False positives in critically ill, TPN patients, prolonged fasting
|
| CT Abdomen/Pelvis |
- Gallstones may or may not be visible (30% radiolucent)
- Normal gallbladder wall
- No inflammatory changes
|
- Gallbladder wall thickening (> 4 mm) and enhancement
- Pericholecystic fat stranding
- Pericholecystic fluid/abscess
- Gallbladder distension
- Complications visible:
- Emphysematous cholecystitis: Gas in wall or lumen
- Gangrenous cholecystitis: Irregular wall, intramural gas
- Perforation: Free fluid, focal wall defect
- Pericholecystic abscess
- Less sensitive than ultrasound for uncomplicated cholecystitis
- Best use: Evaluating complications or unclear diagnosis
|
| Aspect |
Biliary Colic |
Acute Cholecystitis |
| Acute Management |
- Analgesia:
- NSAIDs: Ketorolac 30 mg IV or diclofenac 50-75 mg PO (first-line)
- Opioids: Morphine or hydromorphone if NSAIDs contraindicated or insufficient (avoid in renal colic to prevent masking)
- Antispasmodics: Hyoscine butylbromide (Buscopan) may help smooth muscle spasm
- Antiemetics: Ondansetron 4-8 mg IV/PO or metoclopramide 10 mg IV
- Hydration: IV fluids if vomiting or unable to tolerate PO
- No antibiotics needed (no infection/inflammation)
- Observation: Monitor until symptoms resolve (usually hours)
|
- NPO (nothing by mouth): Bowel rest to decrease gallbladder stimulation
- IV Fluids: Crystalloids for hydration and electrolyte replacement
- Analgesia:
- Opioids: Morphine 2-5 mg IV q2-4h PRN or hydromorphone 0.5-1 mg IV q2-4h PRN
- NSAIDs: May add ketorolac 30 mg IV q6h (avoid if considering surgery due to bleeding risk)
- Antiemetics: Ondansetron 4-8 mg IV q8h PRN
- Antibiotics (broad-spectrum):
- Mild-moderate cholecystitis: Ceftriaxone 1-2 g IV daily + metronidazole 500 mg IV q8h
- Alternative: Piperacillin-tazobactam 3.375 g IV q6h
- Severe/complicated cholecystitis or high-risk patients:
- Piperacillin-tazobactam 4.5 g IV q6h
- OR Meropenem 1 g IV q8h
- OR Imipenem-cilastatin 500 mg IV q6h
- Coverage needed: Gram-negative rods (E. coli, Klebsiella), Enterococcus, anaerobes
- Nasogastric tube: If persistent vomiting or ileus
- Monitor vital signs: Watch for sepsis, peritonitis
|
| Definitive Management |
- Elective laparoscopic cholecystectomy recommended to prevent recurrence
- Timing: Can be scheduled within 6 weeks of initial episode
- Urgency: Not emergent; outpatient surgery
- Risk of recurrence: 30-50% within 1 year if not treated
- Risk of complications: 1-3% per year (cholecystitis, pancreatitis)
- Conservative management: Only if patient refuses surgery or high surgical risk
- Dietary modification: Low-fat diet
- Expectant management with understanding of recurrence risk
- Ursodeoxycholic acid for stone dissolution (limited efficacy, only for small cholesterol stones)
|
- Surgical cholecystectomy (definitive treatment)
- Timing - Two approaches:
- Early laparoscopic cholecystectomy (PREFERRED):
- Timing: Within 72 hours of symptom onset (ideally within 24-48 hours)
- Benefits:
- Shorter hospital stay
- Lower conversion to open rate
- Fewer complications
- Lower overall cost
- Prevents need for readmission
- Recommended by major guidelines (Tokyo Guidelines, SAGES)
- Delayed cholecystectomy:
- Timing: 6-10 weeks after symptoms resolve (cooling-off period)
- Indication: If presenting > 72 hours after onset with severe inflammation, or patient too unstable for early surgery
- Risks: 20-30% require readmission for recurrent symptoms/complications before planned surgery
- Surgical approach:
- Laparoscopic cholecystectomy (first-line): 90-95% successful, less pain, faster recovery
- Conversion to open: If severe inflammation, unclear anatomy, or complications (5-10% of cases)
- Open cholecystectomy: If laparoscopy not feasible
- Intraoperative cholangiography: May be performed to identify CBD stones
- Non-surgical options (for non-operative candidates):
- Percutaneous cholecystostomy: Image-guided drainage tube placement
- Indication: High-risk surgical patients (elderly, severe comorbidities, septic)
- Temporizes infection; cholecystectomy still needed later if patient improves
- May convert to interval cholecystectomy once stabilized
- Antibiotics alone: Success rate 60-80%, but high recurrence (20-40%); not recommended except in very high-risk patients
- Complications requiring urgent intervention:
- Gangrenous cholecystitis: Urgent surgery
- Emphysematous cholecystitis: Urgent surgery + broad-spectrum antibiotics
- Perforation: Emergency surgery
- Gallbladder empyema: Urgent drainage or surgery
|
| Additional Considerations |
- Pre-operative workup:
- Ensure no CBD stones (check LFTs, CBD diameter on ultrasound)
- If concern for choledocholithiasis: MRCP or intraoperative cholangiography
- Patient education: High recurrence rate without surgery
- Dietary advice: Avoid fatty meals temporarily
|
- Grade severity (Tokyo Guidelines):
- Grade I (Mild): No organ dysfunction, healthy patient → Early laparoscopic cholecystectomy
- Grade II (Moderate): Elevated WBC, palpable mass, > 72 hours duration → Early surgery or percutaneous drainage if high risk
- Grade III (Severe): Organ dysfunction (cardiovascular, renal, hepatic, hematologic, neurologic) → Stabilize first, percutaneous drainage, then interval cholecystectomy
- Check for choledocholithiasis:
- If suspected (jaundice, dilated CBD, elevated bilirubin), perform ERCP before or after cholecystectomy
- DVT prophylaxis: Subcutaneous heparin or enoxaparin (hospitalized patients)
|
| Prognosis |
- Excellent with cholecystectomy
- Recurrence prevented with surgery
- Low surgical morbidity (< 5%) and mortality (< 0.5%) for elective laparoscopic cholecystectomy
|
- With early surgery: Excellent outcomes, mortality < 1%
- Complicated cholecystitis:
- Gangrenous cholecystitis: Mortality 15-30%
- Perforation: Mortality 10-30%
- Emphysematous cholecystitis: Mortality 15-25%
- High-risk patients: Elderly, diabetics, immunocompromised have worse outcomes
|